|
Targeting B-cell lymphoma with Leukothera-phase II
|
3R42CA173900-03S1
|
$140,000
|
$140,000
|
BELINKA, BENJAMIN
|
ACTINOBAC BIOMED, INC.
|
|
Epigenetic activity of normal and cancer-associated mutant H1 linker histones
|
1F30CA210539-01
|
$43,576
|
$21,788
|
HEALTON, SEAN
|
ALBERT EINSTEIN COLLEGE OF MEDICINE, INC
|
|
Combination Immunotherapy of a Novel Superagonist IL-15 Complex and Anti-CD20 Antibody for Indolent Non-Hodgkin Lymphoma
|
5R44CA195812-02
|
$966,343
|
$966,343
|
WONG, HING
|
ALTOR BIOSCIENCE CORPORATION
|
|
An Early-Phase Clinical Trial Evaluating ABC294640 in Patients with Refractory/Re
|
5R42CA183708-05
|
$133,116
|
$133,116
|
PARSONS, CHRISTOPHER
|
APOGEE BIOTECHNOLOGY CORPORATION
|
|
SPORE in Lymphoma
|
3P50CA126752-10S1
|
$300,703
|
$84,197
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
SPORE in Lymphoma
|
4P50CA126752-10
|
$2,344,258
|
$656,392
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
Cancer Center Support Grant
|
3P30CA033572-33S1
|
$125,651
|
$10,052
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-33S2
|
$124,999
|
$10,000
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-33S3
|
$37,400
|
$2,992
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
3P30CA033572-33S4
|
$350,000
|
$28,000
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Cancer Center Support Grant
|
4P30CA033572-33
|
$2,520,000
|
$201,600
|
ROSEN, STEVEN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Risk factors for molecular subtypes of NHL a prospective evaluation
|
1R01CA202712-01A1
|
$752,796
|
$752,796
|
WANG, SOPHIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Molecular epidemiology of non-Hodgkin lymphoma prognosis and prevention
|
4R01CA166219-05
|
$561,758
|
$561,758
|
WANG, SOPHIA
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Stem Cell Gene Therapy Following R-EPOCH for Non-Hodgkin Lymphoma in AIDS Patient
|
5U01CA183012-03
|
$106,075
|
$106,075
|
ZAIA, JOHN
|
BECKMAN RESEARCH INSTITUTE/CITY OF HOPE
|
|
Lig4R278H contribution to HSC and IgH class switching defects and malignancies
|
4R01CA161151-04
|
$377,086
|
$188,543
|
YAN, CATHERINE
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S1
|
$1,595,651
|
$79,783
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S2
|
$550,000
|
$27,500
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
3U10CA180821-03S3
|
$750,000
|
$37,500
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Alliance for Clinical Trials in Oncology Operations Center
|
5U10CA180821-03
|
$9,068,022
|
$453,401
|
BERTAGNOLLI, MONICA
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Transforming the diagnosis and care of patients with CTCL using TCR sequencing
|
1R01CA203721-01
|
$742,632
|
$742,632
|
CLARK, RACHAEL
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus Nuclear Protein in B Cell Growth Transformation
|
4R01CA047006-29
|
$565,231
|
$282,616
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Epstein-Barr Virus LMP1-Mediated Oncogenecity
|
4R01CA085180-15
|
$762,316
|
$381,158
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
Roles of Epstein-Barr virus nuclear antigens 2 and LP in B cell proliferation
|
4R01CA170023-04
|
$393,163
|
$196,582
|
KIEFF, ELLIOTT
|
BRIGHAM AND WOMEN'S HOSPITAL
|
|
CAR-T cell control through orthogonal antibody-based switches
|
1R01CA208398-01
|
$419,739
|
$209,870
|
YOUNG, TRAVIS
|
CALIFORNIA INSTITUTE/BIOMEDICAL RESEARCH
|
|
Impact of social and built environments on health-related quality of life for cancer survivors
|
1R03CA202192-01
|
$72,530
|
$14,506
|
SHARIFF-MARCO, SALMA
|
CANCER PREVENTION INSTIT OF CALIFORNIA
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S1
|
$20,833
|
$417
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S2
|
$60,000
|
$1,200
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S3
|
$118,406
|
$2,368
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
3P30CA043703-26S4
|
$200,000
|
$4,000
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
Case Comprehensive Cancer Center Support Grant
|
4P30CA043703-26
|
$4,895,515
|
$97,910
|
GERSON, STANTON
|
CASE WESTERN RESERVE UNIVERSITY
|
|
CWRU Case Comprehensive Cancer Center NCTN Lead Academic Participating Site
|
5U10CA180853-03
|
$1,033,213
|
$51,661
|
MACHTAY, MITCHELL
|
CASE WESTERN RESERVE UNIVERSITY
|
|
COG NCTN Network Group Operations Center
|
3U10CA180886-03S1
|
$3,025,319
|
$242,026
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
COG NCTN Network Group Operations Center
|
5U10CA180886-03
|
$21,084,883
|
$1,686,791
|
ADAMSON, PETER
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Exploring the oncogenic potential of human APOBEC3 cytosine deaminases
|
5R21CA185799-02
|
$219,240
|
$72,349
|
WEITZMAN, MATTHEW
|
CHILDREN'S HOSP OF PHILADELPHIA
|
|
Mechanisms of resistance to ALK inhibitors in ALK-rearranged lymphoma
|
5R01CA196703-02
|
$404,888
|
$404,888
|
CHIARLE, ROBERTO
|
CHILDREN'S HOSPITAL CORPORATION
|
|
Nonadherence: Undermining health outcomes in pediatric HSCT?
|
4R01CA157460-05
|
$407,809
|
$203,905
|
PAI, AHNA
|
CINCINNATI CHILDRENS HOSP MED CTR
|
|
MYC as a Biomarker in Aggressive Non-Hodgkin Lymphoma
|
5R01CA187415-02
|
$439,795
|
$439,795
|
LI, YONG
|
CLEVELAND CLINIC LERNER COM-CWRU
|
|
CSHL Cancer Center Support Grant
|
2P30CA045508-29
|
$4,405,681
|
$44,057
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
Cold Spring Harbor Laboratory Cancer Research Center
|
4P01CA013106-45
|
$4,445,418
|
$133,363
|
STILLMAN, BRUCE
|
COLD SPRING HARBOR LABORATORY
|
|
Identification of Loci Modifying Atm Lymphomagenesis
|
5R01CA197801-02
|
$341,468
|
$170,734
|
WEIL, MICHAEL
|
COLORADO STATE UNIVERSITY
|
|
Defining the functions and translational potential of ferroptosis
|
1R35CA209896-01
|
$809,277
|
$275,154
|
STOCKWELL, BRENT
|
COLUMBIA UNIV NEW YORK MORNINGSIDE
|
|
Enhancing the vaccinal effect of antitumor antibodies
|
4R01CA164309-05
|
$332,000
|
$166,000
|
CHRISTIANO, ANGELA
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Non-catalytic functions of DNA-PK in DNA repair and tumorigenesis
|
5F31CA183504-03
|
$43,576
|
$43,576
|
CROWE, JENNIFER
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
From pathogenesis to new therapeutic targets in Diffuse Large B cell Lymphoma
|
1R35CA210105-01
|
$406,000
|
$406,000
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Role of acetyltransferase gene inactivation in follicular lymphoma pathogenesis
|
4R01CA164152-05
|
$332,000
|
$332,000
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Role of MEF2B mutations in lymphomagenesis
|
5R01CA178453-03
|
$443,555
|
$443,555
|
DALLA-FAVERA, RICCARDO
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S1
|
$120,000
|
$15,600
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S2
|
$60,000
|
$7,800
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S3
|
$121,873
|
$15,843
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
|
Cancer Center Support Grant
|
3P30CA013696-42S4
|
$150,866
|
$19,613
|
EMERSON, STEPHEN
|
COLUMBIA UNIVERSITY HEALTH SCIENCES
|
Total relevant funding to Non Hodgkins Lymphoma for this search: $116,691,276
|